AMEX:STXS

Stock Analysis Report

Executive Summary

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Stereotaxis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.9%

STXS

1.2%

US Medical Equipment

1.0%

US Market


1 Year Return

180.3%

STXS

14.9%

US Medical Equipment

8.0%

US Market

Return vs Industry: STXS exceeded the US Medical Equipment industry which returned 14.9% over the past year.

Return vs Market: STXS exceeded the US Market which returned 8% over the past year.


Shareholder returns

STXSIndustryMarket
7 Day8.9%1.2%1.0%
30 Day-11.7%-2.7%-0.07%
90 Day34.3%-1.7%-1.0%
1 Year180.3%180.3%15.8%14.9%10.4%8.0%
3 Year374.7%374.7%71.4%66.2%46.2%36.7%
5 Year84.5%84.5%124.3%99.7%64.3%46.2%

Price Volatility Vs. Market

How volatile is Stereotaxis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Stereotaxis undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Stereotaxis is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Stereotaxis has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Stereotaxis's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Stereotaxis regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Stereotaxis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Stereotaxis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Stereotaxis performed over the past 5 years?

38.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: STXS is unprofitable, but has reduced losses over the past 5 years at a rate of 38.2% per year.

Accelerating Growth: Unable to compare STXS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STXS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: STXS has a negative Return on Equity (-90.97%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: STXS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: STXS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Stereotaxis's financial position?


Financial Position Analysis

Short Term Liabilities: STXS's short term assets ($15.5M) exceeds its short term liabilities ($12.8M)

Long Term Liabilities: STXS's short term assets (15.5M) exceeds its long term liabilities (3.8M)


Debt to Equity History and Analysis

Debt Level: STXS is debt free.

Reducing Debt: STXS currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: STXS has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if STXS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STXS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: STXS has sufficient cash runway for 2.138019 years if free cash flow continues to grow at historical rates of 20.8% each year.


Next Steps

Dividend

What is Stereotaxis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate STXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate STXS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if STXS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STXS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STXS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Stereotaxis's salary, the management and board of directors tenure and is there insider trading?

4.9yrs

Average management tenure


CEO

David Fischel (32yo)

2.7yrs

Tenure

US$58,500

Compensation

Mr. David Leo Fischel, CFA, CPA has been the Chairman of Stereotaxis, Inc. since February 3, 2017 and has been its Chief Executive Officer since February 3, 2017. Mr. Fischel is a Principal and primary por ...


Management Age and Tenure

4.9yrs

Average Tenure

Experienced Management: STXS's management team is considered experienced (4.9 years average tenure).


Board Age and Tenure

3.1yrs

Average Tenure

63yo

Average Age

Experienced Board: STXS's board of directors are considered experienced (3.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$1,09430 Nov 18
David Benfer
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares760
Max PriceUS$1.44

Ownership Breakdown


Management Team

  • Gery Tomassoni

    Chief Medical Officer

    • Tenure: 7.2yrs
  • J. Burkhardt

    Chief Development Advisor

    • Tenure: 11.8yrs
  • David Fischel (32yo)

    CEO & Chairman

    • Tenure: 2.7yrs
    • Compensation: US$58.50k
  • Kevin Barry

    Chief Legal Officer

    • Tenure: 0.9yrs
    • Compensation: US$218.67k
  • Kim Peery

    Chief Financial Officer

    • Tenure: 0yrs

Board Members

  • Arun Menawat (64yo)

    Independent Director

    • Tenure: 3.1yrs
    • Compensation: US$58.50k
  • Joe Kiani (54yo)

    Independent Director

    • Tenure: 3.1yrs
    • Compensation: US$58.50k
  • Bob Messey (73yo)

    Independent Director

    • Tenure: 14.4yrs
    • Compensation: US$58.50k
  • Nathan Fischel (63yo)

    Director

    • Tenure: 2.7yrs
    • Compensation: US$58.50k
  • David Benfer (72yo)

    Lead Independent Director

    • Tenure: 4.7yrs
    • Compensation: US$58.50k
  • Ross Levin (35yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$39.48k
  • David Fischel (32yo)

    CEO & Chairman

    • Tenure: 2.7yrs
    • Compensation: US$58.50k

Company Information

Stereotaxis, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Stereotaxis, Inc.
  • Ticker: STXS
  • Exchange: AMEX
  • Founded: 1990
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$235.246m
  • Shares outstanding: 66.08m
  • Website: https://www.stereotaxis.com

Number of Employees


Location

  • Stereotaxis, Inc.
  • 4320 Forest Park Avenue
  • Suite 100
  • St. Louis
  • Missouri
  • 63108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STXSAMEX (NYSE MKT LLC)YesCommon SharesUSUSDAug 2004

Biography

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 23:52
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.